<SEC-DOCUMENT>0001104659-15-060018.txt : 20150814
<SEC-HEADER>0001104659-15-060018.hdr.sgml : 20150814
<ACCEPTANCE-DATETIME>20150814151713
ACCESSION NUMBER:		0001104659-15-060018
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150814
FILED AS OF DATE:		20150814
DATE AS OF CHANGE:		20150814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			uniQure N.V.
		CENTRAL INDEX KEY:			0001590560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36294
		FILM NUMBER:		151055226

	BUSINESS ADDRESS:	
		STREET 1:		MEIBERGDREFF 61
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1005 BA
		BUSINESS PHONE:		31-20-5667394

	MAIL ADDRESS:	
		STREET 1:		MEIBERGDREFF 61
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1005 BA

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	uniQure B.V.
		DATE OF NAME CHANGE:	20131030
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a15-17723_16k.htm
<DESCRIPTION>6-K
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;6-K</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Report of Foreign Private Issuer</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Rule&nbsp;13a-16 or 15d-16 of</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">the Securities Exchange Act of 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">August&nbsp;14, 2015</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">uniQure N.V.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">J&#246;rn Aldag, Chief Executive Officer<br> Meibergdreef 61<br> Amsterdam 1105 BA, the Netherlands; Tel: +31 20 566 7394</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address,&nbsp;Including ZIP Code, and Telephone Number,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Including Area Code, of Registrant&#146;s Principal Executive Offices)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;20-F&nbsp;</font><font face="Wingdings">x</font>&nbsp;&nbsp;Form&nbsp;40-F&nbsp;<font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1):&nbsp;</font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(7):&nbsp;</font><font face="Wingdings">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\106466\15-17723-1\task7548323\17723-1-ba.htm',USER='106466',CD='Aug 15 00:32 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Furnished as Exhibit&nbsp;99.1 to this Report on Form&nbsp;6-K is a press release of uniQure N.V. dated August&nbsp;10, 2015, announcing the second closing of the equity component of the Company&#146;s collaboration and license agreement with Bristol-Myers Squibb Company and the receipt by the Company of certain additional payments related to the identification of collaboration targets pursuant to such agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_205342_1264"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\106466\15-17723-1\task7548323\17723-1-ba.htm',USER='106466',CD='Aug 15 00:32 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">UNIQURE   N.V.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: August&nbsp;14,   2015</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ MATTHEW KAPUSTA</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Matthew Kapusta</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_205438_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\106466\15-17723-1\task7548323\17723-1-ba.htm',USER='106466',CD='Aug 15 00:32 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INDEX TO EXHIBITS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="88%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:88.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press release of uniQure N.V. dated August&nbsp;10,   2015, announcing the second closing of the equity component of the Company&#146;s collaboration   and license agreement with Bristol-Myers Squibb Company and the receipt by   the Company of certain additional payments related to the identification of   collaboration targets pursuant to such agreement.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="PB_4_205502_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\106466\15-17723-1\task7548323\17723-1-ba.htm',USER='106466',CD='Aug 15 00:32 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a15-17723_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="214" height="48" src="g177231mmi001.jpg" alt="GRAPHIC"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure Announces Receipt of $53 Million from Bristol-Myers Squibb for<br> Target Selection Payment and Additional Equity Investment</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Amsterdam, the Netherlands, August 10, 2015 </font></b>&#151; uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the receipt of an additional $53 million from Bristol-Myers Squibb in accordance with the companies&#146; strategic collaboration to develop gene therapies to treat a range of cardiovascular diseases. Bristol-Myers Squibb selected three new collaboration targets triggering a $15 million cash payment to uniQure.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Bristol-Myers Squibb also acquired an additional 1.3 million ordinary shares of uniQure priced at $29.67 per share, providing net proceeds to the Company of approximately $38 million. The purchase price represents an approximately 26% premium over uniQure&#146;s closing price per ordinary share on August 7, 2015. After this second equity closing, Bristol-Myers Squibb owns 9.9% of uniQure&#146;s outstanding ordinary shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Our collaboration with Bristol-Myers Squibb has been progressing very well and we admire their drive and commitment to bringing transformational medicine, such as gene therapy, to patients with cardiovascular disease,&#148; said Joern Aldag, Chief Executive Officer of uniQure. &#147;With the recent addition of more than $200 million in capital from our collaboration and the Company&#146;s recent follow-on offering, we have the financial resources to meet the needs of our collaboration and advance the development of our proprietary pipeline focused on CNS and liver-directed diseases.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About the Collaboration Agreement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The collaboration agreement, which closed on May 21, 2015, provides Bristol-Myers Squibb exclusive access to uniQure&#146;s gene therapy technology platform for multiple targets in cardiovascular diseases. The collaboration includes uniQure&#146;s proprietary gene therapy program for congestive heart failure that is intended to restore the heart&#146;s ability to synthesize S100A1, a calcium sensor and master regulator of heart function, and thereby improve clinical outcomes for patients with reduced ejection fraction. Beyond cardiovascular diseases, the agreement also includes the potential for target-exclusive collaboration in other disease areas. In total, the companies may collaborate on up to ten targets, of which four such targets have been designated by Bristol-Myers Squibb to date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In accordance with the terms of the agreement, Bristol-Myers Squibb has made total payments to uniQure of $140 million. uniQure will also be eligible to receive research, development and regulatory milestone payments, including up to $254 million for the lead S100A1 therapeutic and up to $217 million for each other gene therapy product potentially developed under the collaboration. Additionally, uniQure is eligible to receive net sales-based milestone payments and tiered single- to double-digit royalties on product sales. Bristol-Myers-Squibb has been granted two warrants, each to acquire up to an additional 5% equity interest, at a premium, based on additional targets being introduced into the collaboration. The parties have also agreed to enter into a supply contract, under which uniQure will undertake manufacturing of all gene therapy products under the collaboration.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About uniQure</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have the only approved gene therapy product in the European Union. To learn more, please visit www.uniQure.com.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;look forward to&#148;, &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions. Forward-looking statements are based on management&#146;s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the commercial launch of Glybera in the EU, the risk of cessation or delay of any of the ongoing or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kgiri\15-17723-1\task7547878\17723-1-mm.htm',USER='105348',CD='Aug 14 21:21 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">planned clinical studies and/or development of our product candidates, the risk of delay or failure to successfully commercialize or obtain further regulatory approval of our products, and the risk that our collaborations or our other collaboration partners will not continue or will not be successful. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, manufacturing processes and facilities regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading &#147;Risk Factors&#148; in uniQure&#146;s Form 20-F filed with the Securities and Exchange Commission dated April 25, 2014. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Aicha Diba</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct: +31 20 240 6100</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Main: +31 20 566 7394 </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a.diba@uniQure.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Media inquiries:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gretchen Schweitzer or Anca Alexandru </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MacDougall Biomedical Communications </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct: +49 172 861 8540</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Main: +49 89 2424 3494 or +1 781 235 3060 </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">gschweitzer@macbiocom.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kgiri\15-17723-1\task7547878\17723-1-mm.htm',USER='105348',CD='Aug 14 21:21 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g177231mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g177231mmi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  P -8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V6BL&Z\7V
M5I=2P/%.6B8J2 ,9'XULVMPMW:Q3H"%D4, >O-8TZ].I)Q@[M&U3#U*<5*:L
MF2T5F:MKUOH\D23I(QD!(V =J=I.LP:PDK6Z2*(R =X]:?MZ;G[._O=@^KU%
M3]I;W>YHT5GZMK$.CQQO.DC"1BHV"JEMXLT^X25V+PK$ 3O'7/8 =:F6)I1E
MR2E9CCAJTX<\8MHVZ*YL^-[$/@07!7^]@?XUM:?J5MJ<'FVLFX X(/!7ZBBG
MB:-5\L)785,+6I+FG%I#=6GEM=)NIH!F1(R5]O>O.(]0NXKD7"7$OG9SNW$D
M_6O4)G6."1W&5522/45QMOJ7AY;U)8]/F$A88S]T'Z9Q7GYE3YIP?/R_UN>C
MEE3EA->SYOZV9V4+,\*,Z[6902/0UF:[KT6CQJH7S+AQ\J9Z>Y]JUJ\PU>Z:
M\U:YE<YS(0/8#@5OF&*EAZ2Y=V89=A8XBJ^;9$USXBU.Z<EKIT!Z+'\H%-M]
M?U.V8,EY(PST<[@?SKI_#GA^U33XKFZA66:4;AO&0H[8%3Z[X>M+FPEE@@2*
MXC4LI08SCL:\Y8/%.G[;GUWW9Z+QN$53V/)IM>R'Z#XBCU<&*11%<J,E0>&'
MJ*VJ\KL;EK2^@GC.&1P?P[UZF"& (Z'FO0RW%2KP:GNCS\RPD</43ALQ:*YU
M_&EC&[*8;C*D@\#M^-;\4@EB209PZAAGWKKIUZ=5M0=[''5P]2DDYQM<?161
MJOB.VTFZ6">.5F*!\H!C&3_A5G2M5AU>W::!755;:0XYH5>G*?LT]>P/#U(P
M]HUIW+U%9>K:];Z/)&DZ2,9 2-@':H(?%FGR6KSNSQA&VA6'S,?8"E+$T8R<
M')70XX6M**G&+:9MT5S:^-[$O@P3A?[V!_C6Y;7UO=V@N895:$C.[.,?7THI
M8FE5=H2N%7#5:2O.-BQ16!=>,=/@D*1B6?'4H./UI;3QAIUS($D\R DX!D''
MYBI^N4.;EYU<OZEB.7FY'8WJ*0$, 5((/(([T5TG*>9:U_R&KW_KLW\Z] T7
M_D"V?_7%?Y5Y_K7_ "&KW_KLW\Z] T7_ ) MG_UQ7^5>%EG^\5/ZZGO9I_N]
M/^NAS?CG_CZL_P#<;^8JQX%_X][S_?7^1JOXZ_X^K/\ W&_F*L>!?^/>\_WU
M_D:(_P#(R?\ 70)?\BQ?UU%\<_\ 'G:?]=#_ "KF-+TR;5KP008'&YF/1173
M^.?^/.T_ZZ'^54_ W_'_ '7_ %R'\ZSQ-)5<?R2V=OR-,-5E2R_GCNK_ )D.
MJ^$IM.LVN8IQ,B#+@K@@>HJEX<O'L];MRI.V1O+8>H-=[JW_ ""+S_KB_P#(
MUYSI/_(6L_\ KLO\ZG%T(8;$0=+3_ARL'7GB</-5=?\ ACTJ^_X\+C_KDW\J
M\OMO^/F'_?7^=>H7W_'A<?\ 7-OY5Y?;?\?,/^^O\ZVS?^)3,<G_ (=0]68X
M!^E>3SG,TI]6/\Z]9(R"*\GN!B>4>CL/UIYSM#Y_H+)-Y_+]3U#3QC3;8?\
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1VGLU[3XCQJ_L_:/V7P]#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
